TY - JOUR
T1 - Peripheral Polyneuropathy and Female Sexual DysfunctionFamilial Amyloidotic Polyneuropathy as an Example Besides Diabetes Mellitus
AU - Silva, Tânia
AU - Mendes, Jorge
AU - Pinheiro, Luís C.
AU - Barroso, Eduardo
PY - 2013
Y1 - 2013
N2 - Introduction. Female sexual dysfunction (FSD) in peripheral polyneuropathies besides diabetes mellitus is still a poorly studied subject. Little is known about sexual function in women with amyloidosis, GuillainBarre syndrome, or porphyria. Even for the world's most common peripheral polyneuropathies such as diabetes mellitus, knowledge and consensus are still lacking. Familial amyloidotic polyneuropathy (FAP) is the most common cause of genetic systemic amyloidosis, with neurological clinical manifestations similar to diabetes mellitus. Until today, no study on the sexual function of these young female patients has been published. Aim. To evaluate FSD in female FAP patients and to compare the results with those of healthy, non-FAP females. Methods. A questionnaire-based, observational study comprising 94 nonmenopausal women with a sexual partner (51 FAP and 43 non-FAP as the control group) was conducted. The Female Sexual Function Index (FSFI)Portuguese-validated version was used to assess FSD. Main Outcome Measures. Total and subscales scores of the FSFI. Results. FSD was reported by 42\% (95\% confidence intervals {[}CI] 28.355.7) of FAP patients compared to 12\% of healthy controls. Of all the FAP patients, 39.2\% reported problems with desire (95\% CI 25.652.4), 72.5\% reported problems with arousal (95\% CI 60.284.8), 68\% reported lubrication problems (95\% CI 55.180.9), 62\% reported orgasm problems (95\% CI 48.575.5), 39.2\% experienced pain (95\% CI, 25.852.6), and 49\% experienced sexual dissatisfaction (95\% CI, 35.362.7). Even after multiple logistic regression analysis, FAP is associated with sexual dysfunction in women (OR 4.3, 95\% CI 1.215.5, P < 0.03), and the affected domains are desire (OR 5.1, 95\% CI 1.319.7, P < 0.02), arousal (OR 4.7, 95\% CI 1.514.1, P < 0.007), orgasm (OR 5, 95\% CI 1.616, P < 0.007), and sexual satisfaction (OR 4.8, 95\% CI 1.416.9, P < 0.02). Only the use of medication with potential for sexual dysfunction was found as a significant predictor of orgasm disorder (OR 4.2, 95\% CI 1.115.6, P < 0.03), as did age for sexual dissatisfaction (OR 1.1, 95\% CI 1.01.2, P < 0.04). Conclusions. FAP as a peripheral polyneuropathy results in FSD, presenting a risk factor four times greater and related to disease severity in terms of desire, arousal, and orgasm disorders, as well as sexual dissatisfaction. Oliveira-e-Silva T, Campos Pinheiro L, Rocha Mendes J, Barroso E, and Monteiro Pereira N. Peripheral polyneuropathy and female sexual dysfunctionFamilial amyloidotic polyneuropathy as an example besides diabetes mellitus. J Sex Med 2013;10:430-438.}
AB - Introduction. Female sexual dysfunction (FSD) in peripheral polyneuropathies besides diabetes mellitus is still a poorly studied subject. Little is known about sexual function in women with amyloidosis, GuillainBarre syndrome, or porphyria. Even for the world's most common peripheral polyneuropathies such as diabetes mellitus, knowledge and consensus are still lacking. Familial amyloidotic polyneuropathy (FAP) is the most common cause of genetic systemic amyloidosis, with neurological clinical manifestations similar to diabetes mellitus. Until today, no study on the sexual function of these young female patients has been published. Aim. To evaluate FSD in female FAP patients and to compare the results with those of healthy, non-FAP females. Methods. A questionnaire-based, observational study comprising 94 nonmenopausal women with a sexual partner (51 FAP and 43 non-FAP as the control group) was conducted. The Female Sexual Function Index (FSFI)Portuguese-validated version was used to assess FSD. Main Outcome Measures. Total and subscales scores of the FSFI. Results. FSD was reported by 42\% (95\% confidence intervals {[}CI] 28.355.7) of FAP patients compared to 12\% of healthy controls. Of all the FAP patients, 39.2\% reported problems with desire (95\% CI 25.652.4), 72.5\% reported problems with arousal (95\% CI 60.284.8), 68\% reported lubrication problems (95\% CI 55.180.9), 62\% reported orgasm problems (95\% CI 48.575.5), 39.2\% experienced pain (95\% CI, 25.852.6), and 49\% experienced sexual dissatisfaction (95\% CI, 35.362.7). Even after multiple logistic regression analysis, FAP is associated with sexual dysfunction in women (OR 4.3, 95\% CI 1.215.5, P < 0.03), and the affected domains are desire (OR 5.1, 95\% CI 1.319.7, P < 0.02), arousal (OR 4.7, 95\% CI 1.514.1, P < 0.007), orgasm (OR 5, 95\% CI 1.616, P < 0.007), and sexual satisfaction (OR 4.8, 95\% CI 1.416.9, P < 0.02). Only the use of medication with potential for sexual dysfunction was found as a significant predictor of orgasm disorder (OR 4.2, 95\% CI 1.115.6, P < 0.03), as did age for sexual dissatisfaction (OR 1.1, 95\% CI 1.01.2, P < 0.04). Conclusions. FAP as a peripheral polyneuropathy results in FSD, presenting a risk factor four times greater and related to disease severity in terms of desire, arousal, and orgasm disorders, as well as sexual dissatisfaction. Oliveira-e-Silva T, Campos Pinheiro L, Rocha Mendes J, Barroso E, and Monteiro Pereira N. Peripheral polyneuropathy and female sexual dysfunctionFamilial amyloidotic polyneuropathy as an example besides diabetes mellitus. J Sex Med 2013;10:430-438.}
KW - UNCTION-INDEX
KW - DRUGS
KW - POPULATION
KW - AROUSAL
KW - DESIRE
KW - Peripheral Polyneuropathy
KW - Female Sexual Dysfunction
KW - ILLNESS
KW - PREVALENCE
KW - Familial Amyloidotic Polyneuropathy
KW - WOMEN
KW - DISTRESS
KW - IMPACT
U2 - 10.1111/jsm.12013
DO - 10.1111/jsm.12013
M3 - Article
C2 - 23217031
SN - 1743-6095
VL - 10
SP - 430
EP - 438
JO - Journal of Sexual Medicine
JF - Journal of Sexual Medicine
IS - 2
ER -